MedTrace Logo

Iron Therapy in Erythropoietic Protoporphyria

NCT05572125 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2023-02-23

No results posted yet for this study

Summary

Giving oral iron to patients with erythropoietic protoporphyria (EPP) who is iron deficient is thought to be beneficial. This is, however, not well documented. The purpose of this study is to investigate the effect and safety of oral iron in patients with EPP who is taking iron tablets due to iron deficiency.

Conditions

Sponsors & Collaborators

  • Alfred Benzon Foundation

    collaborator UNKNOWN

  • Bispebjerg Hospital

    lead OTHER

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-17
Primary Completion
2023-02-14
Completion
2023-02-14

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05572125 on ClinicalTrials.gov